For the Inventor, By the Inventor

Enter assignee name

Sacramento, CA, United States of America

Genelabs Technologies, Inc.

USPTO Granted Patents = 72

CIPO Patents = 2

Forward Citations = 1,185

Loading Chart...

Loading Chart...

73 inventors (with patents filed for the assignee):

Kirk E Fry (19 out of 39 patents)

Gregory R Reyes (18 out of 27 patents)

Christopher Don Roberts (17 out of 22 patents)

4. Jungsuh P Kim (12 out of 13 patents)

5. Cynthia A Edwards (12 out of 12 patents)

6. Charles Cantor (11 out of 97 patents)

7. Natalia Dyatkina (11 out of 23 patents)

8. Beth M Andrews (11 out of 11 patents)

9. Jesse Daniel Keicher (10 out of 13 patents)

10. Albert W Tam (10 out of 14 patents)

11. Patrice O Yarbough (8 out of 11 patents)

12. Kenneth G Hadlock (6 out of 12 patents)

13. Dong-Fang Shi (6 out of 8 patents)

14. Daniel W Bradley (6 out of 11 patents)

15. Lisa M Turin (6 out of 6 patents)

Core Competencies:

Nucleoside Derivatives

Hepatitis C Virus

Viral Infections

Antifungal Activity

Antibacterial Agents

DNA Binding Compounds

Gene Expression Promoters

Molecular Cloning

Dehydroepiandrosterone

Bone Mineral Density Treatment

Hepatitis E Virus

Nucleic Acid Ligand Interactions

72 patents: Sort by Forward Citations

1. 7612034 - Treatment of subnormal bone mineral density (2009-11-03),

2. 7511145 - Bicyclic heteroaryl derivatives (2009-03-31),

3. 7432248 - Nucleoside derivatives for treating Hepatitis C virus infection (2008-10-07),

4. 7425547 - Nucleoside derivatives for treating hepatitis C virus infection (2008-09-16),

5. 7414031 - 5-nitro-nucleoside compounds for treating viral infections (2008-08-19),

6. 7405204 - Nucleoside compounds for treating viral infections (2008-07-29),

7. 7304085 - Nitrogen-containing heteroaryl derivatives (2007-12-04),

8. 7244713 - Nucleoside compounds for treating viral infections (2007-07-17),

9. 7202223 - Nucleoside compounds for treating viral infections (2007-04-10),

10. 7189506 - DNA binding compound-mediated molecular switch system (2007-03-13),

11. 7169918 - [object Object] (2007-01-30),

12. 7157434 - Nucleoside compounds for treating viral infections (2007-01-02),

13. 7151089 - Nucleoside compounds for treating viral infections (2006-12-19),

14. 7144868 - Nucleoside compounds for treating viral infections (2006-12-05),

15. 7141680 - Aromatic compounds possessing antifungal or antibacterial activity (2006-11-28),

Genelabs Technologies, Inc. is a biotechnology company focused on developing innovative solutions for the diagnosis and treatment of infectious diseases. With a diverse portfolio of patented technologies, Genelabs aims to improve patient outcomes and advance the fields of molecular diagnostics and therapeutics. The company's expertise lies in the development of novel diagnostic tests and potential drug candidates for diseases such as HIV, hepatitis, and respiratory infections.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

72 Patents

#5 in Sacramento, CA

#1,160 in California

#4,870 in US

#9,927 in the World

Sacramento, CA, United States of America

Genelabs Technologies, Inc.

Forward Citations = 1,185

73 inventors:

Kirk E Fry (19 out of 39 patents)

Gregory R Reyes (18 out of 27 patents)

Christopher Don Roberts (17 out of 22 patents)

4. Jungsuh P Kim (12 out of 13 patents)

5. Cynthia A Edwards (12 out of 12 patents)

Please report any incorrect information to support@idiyas.com

Loading…